Rosa Andres Ejarque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rosa Andres Ejarque has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
- María Carmen Terencio
Interuniversity Research Institute for Molecular Recognition and Technological Development (IDM), University of Valencia, Polytechnic University of Valencia, Av. Vicent Andrés Estellés 22, 46100 Burjassot, Valencia, Spain
6 shared publications - Maria Carmen Montesinos
Interuniversity Research Institute for Molecular Recognition and Technological Development (IDM), University of Valencia, Polytechnic University of Valencia, Av. Vicent Andrés Estellés 22, 46100 Burjassot, Valencia, Spain
5 shared publications Miguel Payá
Departament of Pharmacology, Faculty of Pharmacy, University of Valencia, Valencia, Spain; Institute of Molecular Recognition and Technological Development (IDM), Valencia, Spain
5 shared publicationsAnna Chapman
Dermatology Department, Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UK
3 shared publicationsChrysanthi Ainali
St. Johns Institute of Dermatology, Kings College London, London, United Kingdom
3 shared publicationsHemawtee Sreeneebus
St. Johns Institute of Dermatology, Kings College London, London, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Springer Nature in Nature
- Vol. 659 (8140) , 490-501
γδ T cell receptor dependencies define a unique immunosurveillance modality
γδ T cells are one of three lymphocyte lineages that utilize gene rearrangement to diversify their antigen receptors. Nonetheless, the cells’ classification has remained uncertain, complicating our ability to understand the basis for their evolutionary conservation. Whereas many γδ T cells display hallmarks of adaptive immunity, others, including those in barrier tissues, make rapid, reportedly T cell receptor-independent responses that phenocopy innate immune cells 1 . Here we address this paradox and show that the phenotypes of tissue-intrinsic γδ T cells, including their rapid, innate-like responsiveness to tissue stress and carcinogenesis, acutely depend on the γδ T cell receptor (TCRγδ). Those dependencies emphasize the unique biology of γδ T cells and of the immunosurveillance modalities they mediate, with their clinical deployment evidently requiring environments conducive to TCRγδ signalling.
- 30 September 2026
- Published by Springer Nature in Nature
- Vol. 659 (8140) , 490-501
Open Accessγδ T cell receptor dependencies define a unique immunosurveillance modality
γδ T cells are one of three lymphocyte lineages that utilize gene rearrangement to diversify their antigen receptors. Nonetheless, the cells’ classification has remained uncertain, complicating our ability to understand the basis for their evolutionary conservation. Whereas many γδ T cells display hallmarks of adaptive immunity, others, including those in barrier tissues, make rapid, reportedly T cell receptor-independent responses that phenocopy innate immune cells 1 . Here we address this paradox and show that the phenotypes of tissue-intrinsic γδ T cells, including their rapid, innate-like responsiveness to tissue stress and carcinogenesis, acutely depend on the γδ T cell receptor (TCRγδ). Those dependencies emphasize the unique biology of γδ T cells and of the immunosurveillance modalities they mediate, with their clinical deployment evidently requiring environments conducive to TCRγδ signalling.
- Open Access
- 6 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy
Immunotherapy has transformed cancer treatment, including early triple-negative breast cancer (TNBC), yet most patients with advanced TNBC fail to respond to immune checkpoint blockade (ICB) plus chemotherapy. Durable control likely requires not only tumour cell killing but also immunogenic cell death (ICD) that activates antitumour immunity. Using a Brca1 ⁻/⁻ p53 ⁻/⁻ organoid-derived TNBC model that recapitulates the immune landscapes of basal-like tumours, we show that RIPK1-driven ICD synergises with anti-PD-1 therapy to induce durable tumour control and immune memory in immune-infiltrated tumours. Mechanistically, both tumour-intrinsic and stromal necroptosis are required. Deletion of Ripk1 or Mlkl in tumour cells, or Mlkl in the stromal compartment, markedly impairs therapeutic efficacy. Moreover, immunologically “cold” tumours can be rendered responsive to ICD-based therapy by STING agonists. These findings demonstrate that the benefit of IAP antagonism with checkpoint blockade critically depends on coordinated necroptosis in both tumour and stromal cells, underscoring the need to integrate tumour microenvironmental context when designing ICD-targeted immunotherapies.
- 6 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessNecroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy
Immunotherapy has transformed cancer treatment, including early triple-negative breast cancer (TNBC), yet most patients with advanced TNBC fail to respond to immune checkpoint blockade (ICB) plus chemotherapy. Durable control likely requires not only tumour cell killing but also immunogenic cell death (ICD) that activates antitumour immunity. Using a Brca1 ⁻/⁻ p53 ⁻/⁻ organoid-derived TNBC model that recapitulates the immune landscapes of basal-like tumours, we show that RIPK1-driven ICD synergises with anti-PD-1 therapy to induce durable tumour control and immune memory in immune-infiltrated tumours. Mechanistically, both tumour-intrinsic and stromal necroptosis are required. Deletion of Ripk1 or Mlkl in tumour cells, or Mlkl in the stromal compartment, markedly impairs therapeutic efficacy. Moreover, immunologically “cold” tumours can be rendered responsive to ICD-based therapy by STING agonists. These findings demonstrate that the benefit of IAP antagonism with checkpoint blockade critically depends on coordinated necroptosis in both tumour and stromal cells, underscoring the need to integrate tumour microenvironmental context when designing ICD-targeted immunotherapies.
- Top Cited PapersOpen Access
- 20 June 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (18) , 2069-2083
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
PURPOSE: Tumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor. We aimed to characterize mutational and nonmutational mechanisms of p53 dysfunction in myelodysplastic syndromes (MDS) and to investigate their clinical effect. PATIENTS AND METHODS: We analyzed a cohort of 6,204 patients with MDS and subsets of patients with available information on RNA sequencing of tumor cells (n = 109), high-dimensional phenotype of immune cells (n = 77), and multiomics analysis (RNA sequencing and proteomics) on single cells (n = 15). An independent validation was performed on 914 patients. RESULTS: Biallelic TP53 inactivation was a powerful driver of disease progression and identified high-risk patients, regardless of variant allele frequency. Monoallelic and biallelic inactivation represent disease stages occurring as a multihit process in MDS with TP53 mutations, thus potentially refining the optimal timing of therapeutic interventions in these patients. We identified a subset of MDS (5%) characterized by TP53 wild-type and hyperexpression of abnormal p53 protein in bone marrow progenitors that exhibit dismal outcome. These patients presented upstream p53 signaling aberrations in Pi3K cascade; RAS, WNT, and NF-KB pathways; and MDM2 gene amplification, together with a downstream dysregulation of p53 targets. MDS with p53 dysfunction displayed a distinct immune dysregulation involving myeloid-derived inflammation and impaired antigen presentation, which may be a driver of their poor prognosis and provide the groundwork for innovative immunotherapies. CONCLUSION: The identification of nonmutational p53 dysfunction in MDS may lay the foundation for a mechanistic classification of myeloid neoplasms, moving beyond a purely molecular stratification. The recognition of patients with p53 dysfunction is relevant to provide correct disease-risk assessment and interventions, as well as to refine the design of clinical trials
- 20 June 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (18) , 2069-2083
Top Cited PapersOpen AccessCharacterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
PURPOSE: Tumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor. We aimed to characterize mutational and nonmutational mechanisms of p53 dysfunction in myelodysplastic syndromes (MDS) and to investigate their clinical effect. PATIENTS AND METHODS: We analyzed a cohort of 6,204 patients with MDS and subsets of patients with available information on RNA sequencing of tumor cells (n = 109), high-dimensional phenotype of immune cells (n = 77), and multiomics analysis (RNA sequencing and proteomics) on single cells (n = 15). An independent validation was performed on 914 patients. RESULTS: Biallelic TP53 inactivation was a powerful driver of disease progression and identified high-risk patients, regardless of variant allele frequency. Monoallelic and biallelic inactivation represent disease stages occurring as a multihit process in MDS with TP53 mutations, thus potentially refining the optimal timing of therapeutic interventions in these patients. We identified a subset of MDS (5%) characterized by TP53 wild-type and hyperexpression of abnormal p53 protein in bone marrow progenitors that exhibit dismal outcome. These patients presented upstream p53 signaling aberrations in Pi3K cascade; RAS, WNT, and NF-KB pathways; and MDM2 gene amplification, together with a downstream dysregulation of p53 targets. MDS with p53 dysfunction displayed a distinct immune dysregulation involving myeloid-derived inflammation and impaired antigen presentation, which may be a driver of their poor prognosis and provide the groundwork for innovative immunotherapies. CONCLUSION: The identification of nonmutational p53 dysfunction in MDS may lay the foundation for a mechanistic classification of myeloid neoplasms, moving beyond a purely molecular stratification. The recognition of patients with p53 dysfunction is relevant to provide correct disease-risk assessment and interventions, as well as to refine the design of clinical trials
- Open Access
- 8 March 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 173, 116401
Adenosine A2B receptor agonist improves epidermal barrier integrity in a murine model of epidermal hyperplasia
- 8 March 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 173, 116401
Open AccessAdenosine A2B receptor agonist improves epidermal barrier integrity in a murine model of epidermal hyperplasia
- Open Access
- 7 June 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (7) , 1572-1575
A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect
- 7 June 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (7) , 1572-1575
Open AccessA pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect
- Open Access
- 16 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1
Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
- 16 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1
Open AccessAuthor Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
- Open Access
- 8 September 2021
Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
- 8 September 2021
Open AccessEnhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
- Open Access
- 6 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-16
Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
Biologic therapies have transformed the management of psoriasis, but clinical outcome is variable leaving an unmet clinical need for predictive biomarkers of response. Here we perform in-depth immunomonitoring of blood immune cells of 67 patients with psoriasis, before and during therapy with the anti-TNF drug adalimumab, to identify immune mediators of clinical response and evaluate their predictive value. Enhanced NF-κBp65 phosphorylation, induced by TNF and LPS in type-2 dendritic cells (DC) before therapy, significantly correlates with lack of clinical response after 12 weeks of treatment. The heightened NF-κB activation is linked to increased DC maturation in vitro and frequency of IL-17+ T cells in the blood of non-responders before therapy. Moreover, lesional skin of non-responders contains higher numbers of dermal DC expressing the maturation marker CD83 and producing IL-23, and increased numbers of IL-17+ T cells. Finally, we identify and clinically validate LPS-induced NF-κBp65 phosphorylation before therapy as a predictive biomarker of non-response to adalimumab, with 100% sensitivity and 90.1% specificity in an independent cohort. Our study uncovers important molecular and cellular mediators underpinning adalimumab mechanisms of action in psoriasis and we propose a blood biomarker for predicting clinical outcome.
- 6 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-16
Open AccessEnhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
Biologic therapies have transformed the management of psoriasis, but clinical outcome is variable leaving an unmet clinical need for predictive biomarkers of response. Here we perform in-depth immunomonitoring of blood immune cells of 67 patients with psoriasis, before and during therapy with the anti-TNF drug adalimumab, to identify immune mediators of clinical response and evaluate their predictive value. Enhanced NF-κBp65 phosphorylation, induced by TNF and LPS in type-2 dendritic cells (DC) before therapy, significantly correlates with lack of clinical response after 12 weeks of treatment. The heightened NF-κB activation is linked to increased DC maturation in vitro and frequency of IL-17+ T cells in the blood of non-responders before therapy. Moreover, lesional skin of non-responders contains higher numbers of dermal DC expressing the maturation marker CD83 and producing IL-23, and increased numbers of IL-17+ T cells. Finally, we identify and clinically validate LPS-induced NF-κBp65 phosphorylation before therapy as a predictive biomarker of non-response to adalimumab, with 100% sensitivity and 90.1% specificity in an independent cohort. Our study uncovers important molecular and cellular mediators underpinning adalimumab mechanisms of action in psoriasis and we propose a blood biomarker for predicting clinical outcome.
- 1 January 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (1) , 123-131
Adenosine A2A and A2B Receptors Differentially Modulate Keratinocyte Proliferation: Possible Deregulation in Psoriatic Epidermis
- 1 January 2017
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (1) , 123-131
Adenosine A2A and A2B Receptors Differentially Modulate Keratinocyte Proliferation: Possible Deregulation in Psoriatic Epidermis
- Open Access
- 29 June 2015
- Published by Wiley in Experimental Dermatology
- Vol. 24 (10) , 800-802
Decreased SAPK/JNK signalling affects cytokine release and STAT3 activation in psoriatic fibroblasts
- 29 June 2015
- Published by Wiley in Experimental Dermatology
- Vol. 24 (10) , 800-802
Open AccessDecreased SAPK/JNK signalling affects cytokine release and STAT3 activation in psoriatic fibroblasts